Close
The Board carries out wide-ranging consultation on proposals that affect the profession.
The Board may also publish a discussion paper to explore and seek feedback on practice issues that could affect the profession and the public.
Where there are consultations or discussion papers open for input, they will be shown below.
Where there are consultations which have closed, they will be shown under Past Consultations, along with the submissions that were received.
Release: Expected Febuary 2026 Closes: A minimum of eight weeks after release
The Pharmacy Board of Australia will begin public consultation on the development of a draft endorsement for scheduled medicines for pharmacists in early 2026. The consultation will inform the development of a proposal for this endorsement, that if approved by Health Ministers, would create a national qualification requirement that supports safe prescribing by pharmacists.
Having an endorsement for pharmacist prescribing would improve safety by setting consistent qualification requirements across Australia, enable pharmacists to optimise their scope of practice, support workforce mobility and increase access to services.
An endorsement does not authorise pharmacists to prescribe scheduled medicines. These controls are determined by states and territories and set out in local legislation. The proposed endorsement would set a consistent qualification requirement that could then be accepted by each jurisdiction.
More information on this work is available on the Pharmacy Board website.
The consultation pack and response template is expected to be available from February 2026.
When the Board publishes its public consultation material on an endorsement proposal, you will be able to provide feedback by one of two ways:
OR
A link to the online survey will be available from once the consultation is opened.
We will not provide separate responses to individuals who make a submission, but we will publish a summary of the information gathered.
The Board publishes submissions at its discretion. The Board generally publishes submissions on its website to encourage discussion and inform the community and stakeholders. Published submissions will include the names of the individuals and/or the organisations that made them, unless confidentiality is requested.
We will not place on our website, or make available to the public, submissions that contain offensive or defamatory comments or which are outside the scope of the subject of the consultation.
Before publication, we may remove personally identifying information from submissions, including contact details.
